Hypoxia-inducible factor 1 (HIF-1) is a transcriptional activator of various genes related to cellular adaptive responses to hypoxia. Dysfunctions in the regulatory systems of HIF-1 activity have been implicated in the pathogenesis of various diseases including malignant tumors and, thus, elucidating the molecular mechanisms underlying the activation of HIF-1 is eagerly desired for the development of novel anti-cancer strategies. The importance of oxygen-dependent and ubiquitin-mediated proteolysis of the regulatory subunit of HIF-1 (HIF-1a) was first reported in 1997.
| INTRODUCTION
The existence of a hypoxia-inducible transcriptional factor was first predicted in 1991 through an investigation on the cis-acting regulatory elements of the human erythropoietin gene (Epo), the expression of which is known to be induced under hypoxic conditions [4] [5] [6] [7] , the escape of cancer cells from tumor hypoxia (invasion and metastasis of cancer cells 5, 8, 9 ), and the adaption of cancer cells to a hypoxic microenvironment (metabolic reprogramming 7, [10] [11] [12] [13] [14] . As a result of these diverse functions of its downstream genes, HIF-1 has been widely recognized as a rational target for cancer therapy 5, 15, 16 and, thus, marked efforts have been devoted to elucidating the molecular mechanisms underlying its activation.
Regulatory mechanisms, which have the biggest impact on HIF-1 activity, are regulated through post-translational modifications to the HIF-1a protein ( Figure 2 ). The hydroxylation of HIF-1a by oxygen-, iron-, and 2-oxoglutarate (2OG)-dependent dioxygenase enzymes at two specific proline residues (P402 and P564) and one specific asparagine residue (N803) leads to proteolysis and a decrease in the transactivation activity of HIF-1a, respectively, such that HIF-1 may express its transcriptional activity under hypoxic conditions. [17] [18] [19] [20] Consequently, the expression of HIF-1a itself and its downstream genes are detected in hypoxic regions, which are located 70-100 lm from functional blood vessels in malignant solid tumors. 21 However, the expression of HIF-1a is often observed regardless of the distance from functional tumor blood vessels (and potentially regardless of oxygen availability) in immunohistochemical analyses of clinical tumor samples. 22 These findings suggest that there are mechanisms other than the abovedescribed hypoxia-dependent mechanism. In the last decade, HIF-1 activity has consistently been reported to be regulated not only at the post-translational level in an oxygen-dependent way, but also at other levels, such as transcription initiation, translation initiation, heterodimer formation, translocation into the nucleus, and transactivation, regardless of the surrounding oxygen conditions. 11 Moreover, prolyl-and asparagine-hydroxylation-mediated decreases in HIF-1 activity were shown to be abrogated, even in the presence of oxygen, in some cases. 7, 23, 24 We herein review the last two decades of knowledge on the regulatory mechanisms of HIF-1 activity including not only well-established oxygen-and hydroxylation-dependent mechanisms, but also up-to-the-minute information on cancer-associated genetic and functional alteration-mediated mechanisms.
| CONVE NTIONAL DOGMA REGARDING DIOXYGEN ASE-DEPENDE NT REGULATION OF HIF-1 ACTIVITY
After HIF-1 was reported to be a heterodimer, 3 HIF-1a was recognized as the main regulatory subunit for HIF-1 activity, whereas HIF1b was a constitutively expressed subunit. Although the expression levels of HIF-1a are now known to be regulated at multiple levels, the initially elucidated and most influential molecular mechanism on HIF-1 activity is that mediated by the dioxygenase-dependent and ubiquitin-proteasome pathway-mediated system (Figures 1 and 2 ).
Two proline residues positioned at amino acids (a.a.) 402 and 564 of HIF-1a are hydroxylated by dioxygenases, called PHD (including
| 561 PHD1-3), in an oxygen-dependent way (Figures 2 and 3) . 17, 19, 20 Prolyl hydroxylation triggers a ubiquitination reaction by pVHL-containing E3 ubiquitin ligase, leading to the proteolysis of HIF-1a through the ubiquitin-proteasome system with a half-life of 6-8 min (Figure 2) . [25] [26] [27] As HIF-1 promotes angiogenesis by inducing the expression of proangiogenic factors, such as VEGF, this mechanism appears to be reasonable from the viewpoint of a characteristic feature of VHL disease whereby a deficiency in functional VHL as a result of a mutation in chromosome 3p25.3 causes vascular-rich hemangioblastomas, renal cell carcinomas (mainly clear cell carcinomas), and pheochromocytomas. 28, 29 In addition to the proteolytic mechanism triggered by PHD,
another dioxygenase, FIH-1, was found to play a key role in the inactivation of HIF-1 under normoxic conditions (Figures 2 and 3 ).
FIH-1 hydroxylates the asparagine residue positioned at a.a. 803 of HIF-1a in an oxygen-dependent way, and suppresses recruitment of the transcriptional co-activator complex, p300/CBP acetyltransferases, to the HIF-1a protein. 30, 31 Thus, asparagine hydroxylation (Figure 3 ; Tables 1-3) .
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F I G U R E 3 Schematic diagram showing the primary structure and hydroxylated (OH), SUMOylated (Sumo), phosphorylated (P), acetylated (Ac), nitrosylated (NO), and methylated (Me) amino acid residues of the hypoxia-inducible factor 1a (HIF-1a) protein. Gene symbols represented in red and blue indicate positive and negative regulators of hypoxia-inducible factor 1 (HIF-1), respectively. Factors are categorized into 4 groups by dashed squares according to the levels to which HIF-1 activity is regulated; at the level of protein stability (A), interactions with hypoxia-inducible factor 1b (HIF-1b) (B), nuclear translocation (B), and transactivation activity (B). CK1d, casein kinase 1d; C-TAD, Cterminal transactivation domain; FIH-1, factor-inhibiting HIF-1; GSK-3, glycogen synthase kinase 3; HLH, helix-loop-helix; ID, inhibitory domain; IDH, isocitrate dehydrogenase; LSD1, lysine-specific demethylase-1; N-TAD, N-terminal transactivation domain; NQO1, NAD(P)H:quinone oxidoreductase 1; ODD, oxygen-dependent degradation; PAS, Per-Arnt-Sim; PCAF, p300/CBP-associated factor; PHD, prolyl-4-hydroxylase; PLK3, polo-like kinase 3; RSUME, RWD-containing SUMOylation enhancer; SDH, succinate dehydrogenase; SENP, sentrin/SUMO-specific protease; SIRT, sirtuin KOYASU ET AL.
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| Mechanisms regulating HIF-1a mRNA levels
Transcription initiation is generally regarded as one of the most influential steps affecting the expression levels of genes. It is typically stimulated by one or multiple transcription factors that bind to a cognate enhancer sequence in its target promoter region.
Transcription of the HIF-1a gene is not an exception, although basal levels of HIF-1a may be assured regardless of oxygen availability. Previous studies reported that each transcription factor, such as the ISGF3 complex, which is composed of STAT1/STAT2/ IRF9, 37 STAT3, 38 or NF-jB, 39 binds to the promoter region of the HIF-1a gene in order to activate its transcription initiation (Table 1) . Moreover, the PI3K/Akt/PKC/HDAC pathway was also shown to be involved in the up-regulation of HIF-1a transcription when cells had the G13997A mutation in the mitochondrial ND6 gene 40 ( Table 1) . We also identified LY6E as an upstream activator of HIF-1a transcription 6 ( Table 1) . Another mechanism may exist whereby tumor-associated CpG demethylation facilitates the positive autoregulation of HIF-1a expression at the transcription level. (Table 1 ).
In addition to the regulation of transcription initiation efficiency, that for mRNA stability is a key determinant of mRNA expression levels. Regarding HIF-1a mRNA stability, among processing body (Pbody) components, USP52/PAN2 was found to stabilize HIF-1a mRNA by interacting with (or at least by co-localizing with) the 3 0 -untranslated region (UTR) of HIF-1a mRNA, leading to an increase in HIF-1a protein levels 43 (Table 1) .
| Mechanisms regulating the translation initiation of the HIF-1a gene
Translation initiation is another important regulatory step for gene expression, as shown in the regulation of HIF-1a expression levels.
Translation is initiated through a cap-dependent or IRES-dependent mechanism. 44 Regarding HIF-1a, the PI3K/Akt pathway was shown to affect and up-regulate the translational initiation of the HIF-1a protein [45] [46] [47] (Table 1) . YB-1 was also found to directly bind to a unique secondary structure of the 5 0 UTR of HIF-1a mRNA and enhance its translation initiation 48 (Table 1) . Moreover, when activated through replicative stress under hypoxic conditions, ATR was shown to stimulate the translation initiation of the HIF-1a protein through a cis-acting element contained in the HIF-1a open reading frame 49 ( Table 1 ).
| Mechanisms regulating HIF-1a protein stability
The molecular mechanisms regulating the stability of HIF-1a have the greatest impact on HIF-1 activity. In around 2000, the factors responsible, such as VHL and PHD, were cloned one after another, as described earlier 17, 19, 20, 25, 26 ( Figure 1 ). Several gene products with the potential to influence the effects of these two factors on HIF-1a
were subsequently identified as novel indirect modulators of HIF-1 activity. The accumulated metabolites inhibited PHD through product inhibition, whereby the product of an enzymatic reaction directly binds to the enzyme and inhibits its activity for negative feedback regulation, and eventually leads to the stabilization of HIF-1a 23, 24 (Table 2) . IDH has three isoforms, IDH1-3, and their functional disorders or aberrant overexpression influences the function of PHD because of the structural similarity between 2OG and 2HG. Mutations in IDH1/2 have been detected in gliomas or other hematological malignancies. 50 Although the mutant forms of IDH1/2 have been shown to produce 2HG, it currently remains unclear whether 2HG activates or inhibits the activity of PHD or is dependent on the enantiomer, D or L (R or S). For example, Koivunen et al 51 showed that L-2HG inhibits PHD activity, leading to an increase in HIF-1a levels, whereas D-2HG promotes PHD (Table 1) .
Meanwhile, Burr et al 52 reported similar, but controversial, findings
showing that L-2HG inhibits PHD, whereas D-2HG has no effect (Table 2 ). Regarding IDH3, we found that the aberrant activation of wild-type IDH3 inactivated PHD activity by decreasing intracellular levels of 2-OG, resulting in the stabilization of HIF-1a 7 (Table 2) .
Another mechanism has been reported whereby hydroxylation of the two proline residues is actively regulated in order to control the stability of HIF-1a without directly inhibiting the enzymatic activities of PHD. NQO1 was recently identified as a responsible gene 53 (Figure 3A ; Table 2 ). Although NQO1 was originally cloned as a cytosolic reductase, a recent study showed that it binds to the ODD domain of HIF-1a, physically prevents HIF-1a from interacting with PHD, and eventually inhibits the proteasome-mediated degradation of HIF-1a. 53 In an experimental mouse model, knockdown of NQO1 in human colorectal and breast cancer cell lines resulted in suppression of HIF-1 signaling and tumor growth. Clinically, overexpression of NQO1 is associated with poor prognosis of patients with various cancers. 54, 55 Sirtuin 2, which was originally cloned as an isoform of a family of NAD(+)-dependent protein deacetylases that regulate cellular metabolism in response to stress, was recently shown to destabilize HIF-1a using its deacetylase activity 56 ( Figure 3A ; Table 2 ). SIRT2 has been
shown to directly interact with HIF-1a in order to deacetylate HIF-1a
at K709 and enhance the interaction of HIF-1a with PHD2. SIRT2 overexpression was consistently confirmed to destabilize HIF-1a by promoting prolyl-hydroxylation, whereas the HIF-1a protein was maintained at high levels when SIRT2 was deficient or when the acetylation-defective mutation, K709R, was introduced into HIF-1a.
| Mechanisms affecting HIF-1a stability without modulating its prolyl-hydroxylation status
Another type of regulatory mechanism of HIF-1a stability is not mediated by the conventional PHD-VHL system.
A previous study reported that the molecular chaperone 90 kDa HSP90 and RACK1 competitively function to regulate the stability of HIF-1a in a PHD-VHL-independent way 57 ( Table 2) Accumulating evidence has shown that phosphorylation of specific serine and threonine residues of HIF-1a, S551, T555, and S589, all of which are located within the ODD domain, plays an important role in the PHD-VHL-independent destabilization of HIF-1a stability. Glycogen synthase kinase 3 was identified as the gene responsible for phosphorylation based on the finding that the pharmacological inhibition or depletion of GSK-3 induced HIF-1a, whereas overexpression of GSK-3b
reduced HIF-1a, and that mutations in the phosphorylation residues, S551A/T555V/S589A, abolished the destabilization of HIF-1a 58 (Figure 3A ; Table 2 ). This conclusion was further supported by the finding that GSK-3-mediated destabilization of HIF-1a was independent of the hydroxylation sites within HIF-1a (P402/P564/N803) and pVHL.
T ATR, ataxia telangiectasia and Rad3-related protein; HDAC, histone deacetylase; HRE, hypoxia-response element; IRES, internal ribosomal entry site; IRF9, interferon regulatory factor 9; ISGF3, interferon-stimulated gene factor 3; LY6E, lymphocyte antigen 6 complex locus E; ND6, NADH dehydrogenase subunit 6; NF-jΒ, nuclear factor kappa B; NRF-1, NF-E2-related factor 1; PAN2, poly(A) nuclease 2; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; STAT, signal transducer and activator of transcription; USP52, ubiquitin-specific protease 52; YB-1, Y-box-binding protein 1.
Other serine residues, S576 and S657, of HIF-1a were also suggested to be phosphorylated and involved in regulation of HIF-1a stability. 59 The responsible modulator is an evolutionarily conserved serine/threonine kinase, PLK3, which is known to regulate cell cycle progression through the M phase 59,60 ( Figure 3A ; Table 2 ). Xu et al reported that PLK3 physically interacted with HIF-1a under hypoxic conditions and phosphorylated two serine residues, S576 and S657, in order to destabilize HIF-1a. PLK3 knock-out MEF were consistently shown to express higher levels of HIF-1a, whereas the phosphorylation-resistant mutations, S576A and S657A, stabilized HIF1a. In addition, the finding that simultaneous mutations in the prolyl and Plk3-targeting phosphorylation sites (P402A, P564A, S576A, and S657A) further increased the levels of HIF-1a strongly suggested that Plk3 decreases HIF-1a stability in a PHD-independent way.
The SUMOylation of HIF-1a is another post-translational modification that affects HIF-1a stability; however, it currently remains unclear whether SUMOylation increases or decreases the stability of HIF-1a. Bae et al 61 was the first to report in 2004 that SUMOylation increased HIF-1a stability. They identified K391 and K477 of HIF-1a as targets of SUMOylation and showed that overexpression of SUMO-1 increased HIF-1a stability ( Figure 3A ). In 2007, the SUMOylation enzyme for HIF-1a, RSUME, was identified and found to increase the stability of HIF-1a 62 ( Figure 3A ; Table 2 ). However, an opposite function of SUMOylation on the stability of HIF-1a was reported by Cheng et al 63 in an analysis of an isoform of SENP, SENP1 ( Figure 3A ; Table 2 ). They showed that SENP1-mediated deSUMOylation inhibited the interaction between HIF-1a and VHL, resulting in the stabilization of HIF-1a, suggesting that SUMOylation leads to HIF-1a proteolysis. Expression levels of HIF-1 downstream genes were consistently shown to be markedly reduced in MEF and in mice with the homozygous deletion of SENP1.
Besides the major modifications such as ubiquitination, phosphorylation, or SUMOylation described above, methylation also plays a role in modulating HIF-1a stability that is irrelevant to PHD. A recent study showed that HIF-1a is methylated by SET7/9 methyltransferase at K32 64 ( Figure 3A ; Table 2 ), and LSD1 functions in its demethylation 65 ( Figure 3A ; Table 2 ). K32 methylation triggers the ubiquitin-mediated proteolysis of HIF-1a in a PHD-VHL-independent mechanism. Knock-in mice harboring biallelic methylation-defective K32A mutations in the HIF-1a gene showed enhanced retinal angiogenesis and tumor vascularization by HIF-1a stabilization, further supporting the importance of methylation. Mutations near K32 (S28Y and R30Q) of HIF-1a, which have been detected in human cancers, have also been reported to be involved in altered HIF-1a stability affecting K32 methylation. The first factor identified as a deubiquitinating enzyme for HIF1a was VDU2, also known as USP20 66 ( Table 2 ). The interaction between HIF-1a and VDU2 was shown using an immunoprecipitation assay. (Table 2) .
Furthermore, we also identified another deubiquitinating protein, UCHL1, 8 as described below (Table 2) .
| Mechanisms regulating nuclear translocation of HIF-1a
Translocation from the cytosol into the nucleus is another important regulatory step in HIF-1 activity. HIF-1a has the ability to shuttle between the nucleus and the cytoplasm. 68 Carbonaro et al 69 reported
that the HIF-1a protein associates with polymerized microtubules and traffics to the nucleus when its NLS is recognized by the motor protein, dynein (Table 3 ). In addition to this mechanism, the AMPK-HDAC pathway deacetylates the cytosolic molecular chaperone, HSP70, promotes the interaction between HIF-1a and HSP90, and facilitates the rapid nuclear accumulation of HIF-1a 70 (Table 3 ).
In contrast, the active export of HIF-1a from the nucleus was found to be important in the regulation of HIF-1 activity. Phosphorylation of the serine residues, Ser641 and Ser643, which are in close proximity to an atypical nuclear export signal of HIF-1a (between residues 632 and 639), by MAPK has been reported to block export by chromosome region maintenance 1 protein homologue (CRM1), thereby promoting nuclear accumulation and transcriptional activity 68,71,72 ( Figure 3B ; Table 3 ).
| Mechanisms modulating HIF-1a and HIF-1b heterodimer formation
After being stabilized, HIF-1a forms a heterodimer with the constitutively expressed binding partner, HIF-1b. Heterodimer formation is also an important regulatory step in the activation of HIF-1, and
CK1d was found to be involved in this process as a result of this kinase activity on HIF-1a S247 73 ( Figure 3B ; Table 3 ). A luciferase assay to evaluate HIF-1 transcription activity showed that the siRNA-mediated silencing of CK1d enhanced, whereas the overexpression of CK1d inhibited HIF-1 activity under hypoxic conditions.
The phosphorylation-defective mutation, S247A, enhanced, whereas the corresponding phosphorylation-mimic mutation, S247Q, inhibited heterodimerization, further suggesting the importance of the CK1d-dependent phosphorylation of HIF-1a.
| Mechanisms regulating the transactivation activity of HIF-1a
Regulation of the transactivation activity of HIF-1 is primarily modulated by the hydroxylation of N803 by an oxygen-dependent dioxygenase other than PHD, namely, FIH-1 (Figure 2 ). Asparagine hydroxylation prevents the acetyltransferases, p300/CBP, from interacting with the C-terminal transactivation domain (C-TAD) of HIF-1a
and subsequently inhibits the recruitment of RNA polymerase II to the promoter regions of the downstream genes of HIF-1. Thus, factors modulating this process including not only the asparagine hydroxylation status, but also the efficiency of p300/CBP recruitment have been found to affect the transactivation activity of HIF-1.
Another isoform of SIRT2, SIRT1, was shown to suppress the transactivation activity of HIF-1a 74 ( Figure 3B ; Table 3 ). HIF-1a is acetylated by PCAF at K647 ( Figure 3B ; Table 3 ). SIRT1 deacetylates it and represses HIF-1a activity by inhibiting the recruitment of p300/CBP. SIRT1 was down-regulated under hypoxic conditions as a result of reduced NAD(+) levels, which facilitated the acetylation and activation of HIF-1a.
Yasinska and Sumbayev reported the importance of another post-translational modification of HIF-1a, C800 S-nitrosylation, for increases in the transactivation activity of HIF-1a 75 ( Figure 3B ). Snitrosylation was previously reported to stimulate the recruitment of p300 to the HIF-1a C-terminal domain in a GST pull-down assay.
The increase in HIF-1 activity was not observed when the cysteine residue was substituted with alanine.
Chen et al recently reported that XBP1 is activated in triplenegative breast cancers (TNBC) and plays a pivotal role in their tumorigenicity and progression. 76 From a mechanistic viewpoint, they showed that XBP1 formed a transcriptional complex with HIF-T A B L E 2 Positive and negative regulators of hypoxia-inducible factor 1 (HIF-1) functioning at protein stability levels D-2HG, D-2-hydroxyglutarate; FH, fumarate hydratase, FIH-1, factor-inhibiting HIF-1; GSK-3, glycogen synthase kinase 3; HSP, heat-shock protein; IDH, isocitrate dehydrogenase; LSD1, lysine-specific demethylase-1; L-2HG, L-2-hydroxyglutarate; NQO1, NAD(P)H:quinone oxidoreductase 1; PHD, prolyl-4-hydroxylase; PLK3, polo-like kinase 3; RACK1, receptor for activated C kinase; RSUME, RWD-containing SUMOylation enhancer; SDH, succinate dehydrogenase; SENP, sentrin/SUMO-specific protease; SIRT, sirtuin; VDU, pVHL-interacting deubiquitinating enzyme; VHL, von Hippel-Lindau; 2OG, 2-oxoglutarate.
1a, enhancing the expression of HIF-1a target transcripts by recruitment of RNA polymerase II (Table 3) . Depletion of XBP1 inhibited tumor growth and relapse.
| SCREENING OF NOVEL UPSTREAM ACTIVATORS OF HIF-1
We recently established a genetic screening method to investigate novel genes responsible for the activation of HIF-1, and successfully identified the following three genes as novel activators of HIF-1:
IDH3 (Tables 2 and 3), UCHL1 (Table 2) , and LY6E [6] [7] [8] (Table 1) . We reported that the forced expression of each promoted the malignant progression and/or growth of tumors through a different mechanism for the activation of HIF-1.
| IDH3-HIF-1 axis
Aberrant overexpression of wild-type IDH3a, a subunit of the IDH3 heterotetramer, significantly decreased 2OG levels and increased the stability and transactivation activity of HIF-1a in cancer cells by inactivating 2OG-as well as the oxygen-dependent dioxygenases (Tables 2 and 3) , PHD and FIH-1. 7 However, the silencing of IDH3a 
| UCHL1-HIF-1 axis
Regarding UCHL1, we showed that it stabilizes the HIF-1a protein by deconjugating the VHL-mediated ubiquitin from HIF-1a 8 ( Table 2) . In murine models of pulmonary metastasis, the aberrant overexpression of UCHL1 was shown to promote distant tumor metastases in a HIF-1-dependent way. In contrast, the inhibition of the UCHL1-HIF-1 axis resulted in significant suppression of metastatic tumor formation. Intratumoral expression levels of UCHL1
were found to correlate with those of HIF-1a and be strongly associated with the poor overall survival of patients with breast and lung cancers. These findings collectively provide a rationale for using UCHL1 as a prognostic marker and therapeutic target of cancers. In addition, we recently reported that UCHL1 increased the radioresistance of cancer cells by producing the antioxidant, reduced glutathione (GSH), through HIF-1-mediated reprogramming of the glucose metabolic pathway. 77 
| LY6E-HIF-1 axis
Regarding LY6E, we showed that it induced HIF-1a expression principally at the transcription level 6 (Table 1) . This, in turn, increased the expression levels of proangiogenic factors, such as VEGFA and platelet-derived growth factor subunit B (PDGFB), by decreasing those of phosphatase and tensin homolog (PTEN) and subsequently activating the PI3K/Akt pathway. The LY6E-mediated activation of HIF-1 was found to eventually increase micro blood vessel density and promote the growth of tumor xenografts in in vivo mouse models. Expression levels of LY6E were significantly higher in human breast cancers than T A B L E 3 Positive and negative regulators of hypoxia-inducible factor 1 (HIF-1) functioning at other levels in normal breast tissues, and were strongly associated with the poor prognoses of patients with various cancers. 
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